Syntara (ASX:SNT) — Material Events
ASX:SNT · 17 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Syntara Advances Clinical Trials and Secures EMA Orphan Drug StatusHigh
Syntara advances clinical pipeline with key trials and regulatory milestones; $12.3M proforma cash at year-end
29 Jan 2026
·Quarterly Activity and Cash Flow Report
·85
Syntara’s Amsulostat Shows Strong Phase 2a Results in Myelofibrosis TrialMedium
Syntara reports positive Phase 2a data for amsulostat in myelofibrosis, advancing clinical development
30 Sept 2025
·Clinical Trial Results
·85
Syntara’s Amsulostat Shows Durable Symptom Relief in Myelofibrosis Phase 2a TrialMedium
Syntara reports positive Phase 2a data for amsulostat in myelofibrosis treatment
30 Sept 2025
·Clinical Trial Results
·85
Syntara’s Amsulostat Shows Durable Benefits in Myelofibrosis Phase 2a TrialMedium
Syntara reports strong Phase 2a results for amsulostat in myelofibrosis, advances clinical pipeline, and maintains solid cash position
28 Oct 2025
·Quarterly Activity Report and Appendix 4C
·85
Syntara Advances Topical Scar Treatment SNT-9465 to Phase 1b After Promising Phase 1aMedium
Syntara advances topical anti-fibrotic SNT-9465 to Phase 1b after positive Phase 1a results
26 Nov 2025
·Media Release
·85
Syntara Narrows Loss, Advances Amsulostat with FDA Fast Track and $20M Capital RaiseMedium
Syntara reports reduced loss, advances clinical trials with FDA Fast Track for amsulostat, raises $20M capital
28 Aug 2025
·Appendix 4E Preliminary Final Report
·85
Garvan Institute Secures $3M Grant to Test Syntara’s Drug in Pancreatic Cancer TrialMedium
Syntara-backed Garvan Institute wins $3M MRFF grant for pancreatic cancer trials with amsulostat
21 Jan 2026
·Media Release
·85
Syntara Secures A$10 Million to Fuel Clinical Trials After FDA NodMedium
Syntara raises A$10 million to advance clinical trials and pipeline after positive FDA feedback
29 Apr 2026
·Capital Raising
·85
Syntara Advances Amsulostat with FDA Fast Track and New TrialsHigh
Syntara reports positive Phase 2 data, FDA Fast Track for amsulostat, and advances multiple clinical trials
30 July 2025
·Quarterly Activities and Cashflow Report
·85
Syntara Doses First Patient in Promising Anti-Scar Drug TrialMedium
Syntara initiates Phase 1a/b trial for topical anti-scarring drug SNT-9465
29 July 2025
·Clinical Trial Update
·80
Syntara Charts FDA-Backed Phase 2 Path for Amsulostat in MyelofibrosisMedium
Syntara receives FDA guidance to conduct Phase 2 controlled trial for amsulostat in myelofibrosis
11 Aug 2025
·Media Release
·80
Syntara Doses First Patient in Pioneering Keloid Scar TrialMedium
Syntara initiates Phase 1c trial for topical keloid scar treatment, plans Phase 1 for hypertrophic scars
15 July 2025
·Media Release
·70
Syntara Unveils Next Steps for Amsulostat in Investor WebinarMedium
Syntara schedules investor webinar to update on amsulostat clinical progress
11 Aug 2025
·Investor Webinar Announcement
·70
Syntara Launches $2M Share Plan at 15.6% Discount After $8M PlacementMedium
Syntara launches A$2 million Share Purchase Plan at A$0.027 per share following A$8 million placement
14 May 2026
·Capital Raising
·70
Syntara Raises $8.84M to Back Five Clinical Trial Readouts Through Share Purchase PlanMedium
Syntara completes $0.84M Share Purchase Plan, total raise $8.84M to fund clinical trials and development
10 June 2026
·Capital Raising
·70
Syntara Raises $18.5M, Navigates $3.7M Operating Cash OutflowMedium
Syntara posts AUD 3.7M operating cash outflow, raises AUD 18.5M financing, ends quarter with AUD 15.1M cash
1 Aug 2025
·Quarterly Cash Flow Report
·50
Syntara Limited Resumes Trading After Quarterly Reports FiledMedium
Syntara Limited reinstated to ASX quotation after quarterly report lodgement
4 Aug 2025
·Reinstatement to Quotation
·50
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Syntara (ASX:SNT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026